GENINUS Inc. (KOSDAQ:389030)

Market Cap	99.59B +77.7%
Revenue (ttm)	10.24B +39.8%
Net Income	-17.03B
EPS	-511.11
Shares Out	33.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	349,220
Open	2,900.00
Previous Close	2,870.00
Day's Range	2,850.00 - 3,130.00
52-Week Range	1,490.00 - 6,480.00
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2025, GENINUS's revenue was 10.48 billion, an increase of 62.40% compared to the previous year's 6.46 billion. Losses were -17.37 billion, 41.6% more than in 2024.